AXA IM hires new head of EM fixed income
AXA Investment Managers has appointed Michael Ganske as head of emerging markets fixed income, based in London.
Axa
-
-
AXA IM launches absolute return service
AXA Investment Managers (AXA IM) has re-hired Pierre-Emmanuel Juillard to spearhead the firm’s new liquid absolute return strategies service.
-
Caspar Rock exits Architas to join Cazenove
Caspar Rock is leaving Architas to join Cazenove Capital Management as its new chief investment officer.
-
Investor fears see gold return to top traded funds list
The BlackRock Gold and General Fund has returned to the list of top traded funds on the Share Centre.
-
RLAM hires Axa’s Marwood
Royal London Asset Management has appointed Richard Marwood as senior fund manager.
-
Axa’s Thomas on consumers, cash flow and retirement
One of the most celebrated equity managers in the UK, Nigel Thomas discusses everything from consumer stocks to the intellectual challenge of fund management.
-
From ESG ETFs to open-ended infrastructure: the week in product news
Blackrock, JP Morgan, Bluebay, AXA, Wermuth and GCP all launched new products this week.
-
AXA expands biotech and healthcare team
AXA Investment Managers hires Peter Hughes as a healthcare equity analyst to its biotech and healthcare team.
-
Vanguard finds advisers split on robo-advice
Two-fifths of UK wealth managers believe robo-advice offers the potential for greater efficiency and to attract new clients in the next five years, according to a survey from Vanguard.
-
AXA to sell off wealth division, reports say
AXA will divest part of its UK business, including the wealth management division, according to media reports.
-
Making hay from volatility
Four main themes have been driving the recent volatility in markets: China, commodities, the Federal Reserve and idiosyncratic risk.
-
HEAD-TO-HEAD: Axa Framlington Biotech vs Polar Capital Healthcare Opportunities
In this week’s Head-to-Head, Gavin Haynes, managing director at Whitechurch Securities, matches up two medical heavyweights – Axa Framlington Biotech and Polar Capital Healthcare Opportunities.